Prolife at MEDICA 2026: Clinically Validated Cardiovascular Monitoring for Home Care
The 2026 edition introduces a new thematic structure covering clinical diagnostics, digital medicine, artificial intelligence, integrated care and homecare. Prolife will exhibit in Hall 11, dedicated to Healthcare Delivery & Clinical Excellence.
At the centre of the Prolife showcase — Prolife PX7 Premium and two technologies that bring blood pressure measurement and atrial fibrillation screening into one intelligent measurement process.
Blood Pressure and Atrial Fibrillation in One Measurement
Hypertension and atrial fibrillation are two leading risk factors for stroke. Prolife brings both into a single blood pressure measurement.
Regular home monitoring identifies elevated blood pressure and pulse patterns for further clinical assessment.
Prolife PX7 Premium combines clinically validated blood pressure measurement with atrial fibrillation screening in one intelligent process. The device supports cardiovascular monitoring at home through clinical accuracy, individual adaptation and technologies integrated into every reading.
Prolife PX7 Premium: AFibra™ SMART and AIm Technologies
AFibra™ SMART technology detects atrial fibrillation during cuff inflation — automatically, with no additional action from the user. About 40% of people with AF show no symptoms. Regular home measurement with AFibra™ SMART gives every person a chance to act before a silent condition becomes a clinical event.
AFibra™ SMART serves as a screening aid and does not replace an ECG or diagnosis by a healthcare professional.
AIm (Artificial Intelligence measurement) technology makes every Prolife reading individual. The measurement process adapts to the person — to their body, their physiology and their condition. The result is accuracy and comfort that feel personal, whoever is measuring and whenever they measure.
The blood pressure measurement accuracy of PX7 Premium has been clinically validated according to the AAMI/ESH/ISO Universal Standard ISO 81060-2:2018, including AMD1:2020 and AMD2:2024. The device is listed by STRIDE BP as a Preferred Device and features a validated cuff range of 22–45 cm.
This approach reflects the Prolife philosophy: health demands control before risks become threats.
Clinical Technology for Home Monitoring
MEDICA connects medical technology with the people who evaluate, recommend and bring healthcare solutions into clinical practice and home care.
For healthcare organisations and distribution partners, PX7 Premium offers a solution with clear market differentiation, grounded in clinical validation and recognised international standards. AF screening during regular blood pressure measurement creates a relevant proposition for professional recommendation and cardiovascular monitoring portfolios.
At MEDICA 2026, the Prolife team will meet physicians, healthcare companies and international partners to discuss the role of clinically validated home monitoring in cardiovascular care.
Meet Prolife at MEDICA 2026
📍 16–19 November 2026
📍 Messe Düsseldorf, Germany
📍 Hall 11, Stand A18
We measure differently.